Cytos Biotechnology AG was formed in 1996 as a spinoff from the Swiss Federal Institute of Technology to develop manufacturing processes for the first four biotech drugs that will go off patent.

This original technology for the production of pharmaceutical proteins has been licensed to pharma companies, which have one of the proteins in Phase III trials, and has helped to fund the company. But the real goal of Cytos is to use knowledge of the immune system gained from virology research to develop Immunodrugs to replace monoclonal antibodies.